SCHEMBL6419259

SCHEMBL6419259

Oc1ccc(Cl)cc1C=NNc1nc2nonc2nc1Nc1ccc(F)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.42
MAPT P10636 5/20 0.42
TP53 P04637 3/20 0.42
POLB P06746 3/20 0.42
CCR2 P41597 1/20 0.40
CCR5 P51681 1/20 0.40
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
KDM4E B2RXH2 2/20 0.37
RAB9A P51151 2/20 0.37
GRM4 Q14833 1/20 0.37
NPC1 O15118 1/20 0.37
MITF O75030 1/20 0.37
GPR174 Q9BXC1 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
EGFR P00533 4/20 0.37
BRAF P15056 2/20 0.36
RAF1 P04049 1/20 0.36
ALDH1A1 P00352 2/20 0.36
DDX3X O00571 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419770 0.90 DDX3X (0.45) SMN1; SMN2MAPTTP53POLBCCR2
SCHEMBL6418421 0.90 SMN1; SMN2 (0.44) SMN1; SMN2MAPTTP53POLBCCR2
SCHEMBL6417851 0.89 APP (0.42) SMN1; SMN2MAPTTP53POLBCCR2
SCHEMBL6417858 0.89 APP (0.42) SMN1; SMN2MAPTTP53POLBCCR2
SCHEMBL6440416 0.87 MEN1 (0.47) SMN1; SMN2MAPTTP53POLBCCR2
SCHEMBL6418357 0.87 MAPT (0.47) SMN1; SMN2MAPTTP53POLBCCR2
SCHEMBL6416317 0.86 MAPT (0.45) SMN1; SMN2MAPTTP53POLBMEN1
SCHEMBL6418326 0.84 GAA (0.47) SMN1; SMN2MAPTTP53POLBCCR2
SCHEMBL6432545 0.83 APP (0.42) SMN1; SMN2MAPTTP53CCR2CCR5
SCHEMBL6432537 0.83 APP (0.42) SMN1; SMN2MAPTTP53CCR2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 SMN1; SMN2 4369/4885MAPT 4420/4885TP53 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.